Uniphar PLC Consent to Migration (2547Q)
February 25 2021 - 1:00AM
UK Regulatory
TIDMUPR
RNS Number : 2547Q
Uniphar PLC
25 February 2021
UNIPHAR PLC CONSENTS TO THE MIGRATION OF ORDINARY SHARES TO
EUROCLEAR BANK'S CENTRAL SECURITIES DEPOSITORY
Dublin, London | 25 February 2021
As previously announced, the shareholders of the Company
approved resolutions in relation to the replacement of CREST with a
system operated by Euroclear Bank for the electronic settlement of
trading in Uniphar Shares at the extraordinary general meeting held
on 15 February 2021 ("EGM").
In accordance with Resolution 1 approved at the EGM, on 16
February 2021 a committee of the board of directors of the Company
approved the Company giving its consent to the Migration of the
Migrating Shares to Euroclear Bank's central securities depository
in accordance with the Migration of Participating Securities Act
2019. The requisite notifications in connection with the Migration
have also been made by the Company to the Irish Companies
Registration Office and Euronext Dublin.
The Migration will take place as part of the wider Market
Migration which will occur on the date determined by Euronext
Dublin and which is currently expected to be on or around 15 March
2021. Further announcements will be made in relation to the
Migration timetable in due course.
--- ENDS ---
For further details contact:
Uniphar +353 (0) 1 428 7777
Brian O'Shaughnessy
------------------------------
Group Director of Corporate Development investor.relations@Uniphar.ie
------------------------------
Davy +353 (0) 1 679 6363
------------------------------
(Joint Corporate Broker, Nominated Adviser
and Euronext
Growth Adviser)
------------------------------
Fergal Meegan
------------------------------
Barry Murphy
------------------------------
Orla Cowzer
------------------------------
RBC Capital Markets (Joint Corporate Broker) +44 (0) 20 7653 4000
------------------------------
Darrell Uden
------------------------------
Jonathan Hardy
------------------------------
Jamil Miah
------------------------------
Stifel Nicolaus Europe Limited (Joint Corporate
Broker) +44 (0) 20 7710 7600
------------------------------
Matt Blawat
------------------------------
Ben Maddison
------------------------------
Francis North
------------------------------
Q4 PR
+353 (0) 1 475 1444
or
------------------------------
(Public Relations Adviser to Uniphar) +353 87 235 6461
------------------------------
Iarla Mongey
------------------------------
About Uniphar plc
Headquartered in Dublin, Ireland, Uniphar plc is an
international diversified healthcare services business, servicing
the requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail.
The Group has strong established relationships with 7 of the top
10 pharma companies and 6 of the top 10 medical device companies.
With more than 2,500 colleagues, the Group is active in Ireland,
the UK, the Benelux, the Nordics and the US, delivering unlicensed
and specialty medicine on a global basis.
The Group's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth and
profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing
& distribution solutions to multinational pharmaceutical and
medical device manufacturers on an outsourced basis. Active in
Ireland, the UK, the Benelux, and the Nordics, the Group is growing
with its clients to provide pan-European solutions. Uniphar has
built a fully integrated multi-channel solution that is supported
by highly experienced, clinically trained teams to deliver
exceptional outcomes for all clients.
Product Access
In Product Access the Group is growing two distinct service
offerings: 1) "On Demand Access", which are pharmacy led solutions
for sourcing and supplying unlicensed medicines to meet the needs
of both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with over a
50% market share in the wholesale/hospital market, supported by a
network of c.335 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are utilised for the benefit of the growth
divisions, Commercial & Clinical and Product Access.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUSVNRAVUUUAR
(END) Dow Jones Newswires
February 25, 2021 02:00 ET (07:00 GMT)
Uniphar (LSE:UPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Uniphar (LSE:UPR)
Historical Stock Chart
From Apr 2023 to Apr 2024
